Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
<h4>Background</h4>Current treatment recommendations for resectable or borderline pancreatic carcinoma support upfront surgery and adjuvant therapy. However, neoadjuvant therapy (NT) seems to increase prognosis of pancreatic carcinoma and come to everyone's attention gradually. Rand...
Saved in:
| Main Authors: | Lu Huan, Fucai Yu, Ding Cao, Hantao Zhou, Maoling Qin, Yang Cao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0295983&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery
by: Tomofumi Tsuboi, et al.
Published: (2016-01-01) -
Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis
by: S. Banks, et al.
Published: (2024-03-01) -
Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma
by: Jun-Peng Lin, et al.
Published: (2025-08-01) -
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01) -
Single vein resection in surgery for pancreatic ductal carcinoma as a criterion of resectability
by: D. A. Chichevatov, et al.
Published: (2022-09-01)